Tosk Incorporated is a biopharmaceutical company dedicated to improving outcomes for cancer patients by developing new drugs to improve the safety and efficacy of existing therapies.
Side effects limit the use and effectiveness of many of today’s pharmaceutical products. Tosk employs proprietary methods to discover and develop new drugs that reduce or eliminate the adverse effects of existing pharmaceuticals while maintaining their efficacy. This approach not only improves upon proven treatment regimens, but also has the potential to deliver these drugs to the medical community more quickly and with lower research and development costs than is typically required for an entirely new drug.
Tosk has also recently developed new technology to discover drugs that block the action of cancer genes. This technology is being deployed to identify new drugs to make certain cancer drugs effective in patients who do not currently benefit from treatment. The technology may also lead to the discovery of new drugs for direct treatment of certain cancers.